Conclusions

In spite of the enormous efforts devoted to the identification and development of receptor tyrosine kinase inhibitors as new antitumor agents, only two compounds have so far been approved for the treatment of malignancies in which the importance of the targeted kinase is well established. Although it is impossible to predict if new receptor tyrosine kinase inhibitors are going to reach the marketplace in the near future, some of the disappointing clinical results obtained with early kinase inhibitors call for improvements in the selection of clinical candidates and in the clinical development of these targeted antitumor agents. We can only hope that attention to the problems and issues already identified in this challenging area of drug discovery (192) could increase the odds of these agents to alter the natural course of the disease they are targeting and positively impact the lives of cancer patients.

0 0

Post a comment